Kelsey Goodwin
Stock Analyst at Piper Sandler
(4.83)
# 81
Out of 5,081 analysts
26
Total ratings
77.27%
Success rate
43.41%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kelsey Goodwin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BDTX Black Diamond Therapeutics | Assumes: Overweight | $9 | $2.69 | +234.57% | 1 | Nov 18, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Overweight | $25 → $26 | $8.31 | +212.88% | 1 | Nov 5, 2025 | |
| NUVL Nuvalent | Maintains: Overweight | $112 → $128 | $106.90 | +19.74% | 4 | Oct 27, 2025 | |
| SMMT Summit Therapeutics | Initiates: Neutral | $21 | $18.37 | +14.32% | 1 | Aug 19, 2025 | |
| JANX Janux Therapeutics | Initiates: Overweight | $42 | $17.11 | +145.47% | 1 | Aug 19, 2025 | |
| RVMD Revolution Medicines | Initiates: Overweight | $75 | $77.69 | -3.46% | 1 | Aug 19, 2025 | |
| URGN UroGen Pharma | Initiates: Overweight | $36 | $24.35 | +47.84% | 4 | Aug 19, 2025 | |
| CGON CG Oncology | Initiates: Overweight | $55 | $42.61 | +29.08% | 1 | Aug 19, 2025 | |
| TNGX Tango Therapeutics | Initiates: Overweight | $11 | $9.57 | +14.94% | 1 | Aug 19, 2025 | |
| BCAX Bicara Therapeutics | Initiates: Overweight | $36 | $18.16 | +98.24% | 1 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $0.51 | - | 3 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $4.65 | +72.04% | 1 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.40 | - | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | n/a | $72.94 | - | 3 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $27.75 | - | 1 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $2.21 | - | 1 | Oct 31, 2022 |
Black Diamond Therapeutics
Nov 18, 2025
Assumes: Overweight
Price Target: $9
Current: $2.69
Upside: +234.57%
Day One Biopharmaceuticals
Nov 5, 2025
Maintains: Overweight
Price Target: $25 → $26
Current: $8.31
Upside: +212.88%
Nuvalent
Oct 27, 2025
Maintains: Overweight
Price Target: $112 → $128
Current: $106.90
Upside: +19.74%
Summit Therapeutics
Aug 19, 2025
Initiates: Neutral
Price Target: $21
Current: $18.37
Upside: +14.32%
Janux Therapeutics
Aug 19, 2025
Initiates: Overweight
Price Target: $42
Current: $17.11
Upside: +145.47%
Revolution Medicines
Aug 19, 2025
Initiates: Overweight
Price Target: $75
Current: $77.69
Upside: -3.46%
UroGen Pharma
Aug 19, 2025
Initiates: Overweight
Price Target: $36
Current: $24.35
Upside: +47.84%
CG Oncology
Aug 19, 2025
Initiates: Overweight
Price Target: $55
Current: $42.61
Upside: +29.08%
Tango Therapeutics
Aug 19, 2025
Initiates: Overweight
Price Target: $11
Current: $9.57
Upside: +14.94%
Bicara Therapeutics
Aug 19, 2025
Initiates: Overweight
Price Target: $36
Current: $18.16
Upside: +98.24%
Mar 28, 2025
Reiterates: Buy
Price Target: n/a
Current: $0.51
Upside: -
Oct 29, 2024
Initiates: Buy
Price Target: $8
Current: $4.65
Upside: +72.04%
Jul 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.40
Upside: -
Jun 20, 2023
Maintains: Buy
Price Target: n/a
Current: $72.94
Upside: -
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $27.75
Upside: -
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $2.21
Upside: -